🧪Top Spanish hospitals adopt the MAF Test, by #IRBBarcelona spinoff #Inbiomotion, to improve breast cancer treatment. This test helps oncologists determine which #BreastCancer patients should be treated with bisphosphonates to improve their prognosis & survival.
➡️ shorturl.at/AbzSI
🎥 Credit: 3Cat
➡️ shorturl.at/AbzSI
🎥 Credit: 3Cat
July 18, 2025 at 8:57 AM
🧪Top Spanish hospitals adopt the MAF Test, by #IRBBarcelona spinoff #Inbiomotion, to improve breast cancer treatment. This test helps oncologists determine which #BreastCancer patients should be treated with bisphosphonates to improve their prognosis & survival.
➡️ shorturl.at/AbzSI
🎥 Credit: 3Cat
➡️ shorturl.at/AbzSI
🎥 Credit: 3Cat
Top Spanish hospitals adopt the MAF Test, developed by @irbbarcelona.org #spinoff #InBioMotion, to improve #BreastCancer treatment
MAF helps determine which patients should be treated with bisphosphonates, improving prognosis & survival #BISTCommunity #PersonalisedMedicine
bist.eu/top-spanish-...
MAF helps determine which patients should be treated with bisphosphonates, improving prognosis & survival #BISTCommunity #PersonalisedMedicine
bist.eu/top-spanish-...
July 23, 2025 at 12:40 PM
Top Spanish hospitals adopt the MAF Test, developed by @irbbarcelona.org #spinoff #InBioMotion, to improve #BreastCancer treatment
MAF helps determine which patients should be treated with bisphosphonates, improving prognosis & survival #BISTCommunity #PersonalisedMedicine
bist.eu/top-spanish-...
MAF helps determine which patients should be treated with bisphosphonates, improving prognosis & survival #BISTCommunity #PersonalisedMedicine
bist.eu/top-spanish-...
🧪Top Spanish hospitals adopt the MAF Test to improve breast cancer treatment. This pioneering test by #IRBBarcelona spinoff #Inbiomotion helps oncologists determine which #BreastCancer patients should be treated with bisphosphonates to improve their prognosis & survival.
➡️ https://shorturl.at/AbzSI
➡️ https://shorturl.at/AbzSI
July 17, 2025 at 9:02 AM
🧪Top Spanish hospitals adopt the MAF Test to improve breast cancer treatment. This pioneering test by #IRBBarcelona spinoff #Inbiomotion helps oncologists determine which #BreastCancer patients should be treated with bisphosphonates to improve their prognosis & survival.
➡️ https://shorturl.at/AbzSI
➡️ https://shorturl.at/AbzSI
#PortfolioNews I Inbiomotion continues to expand its #international presence, with distribution partnerships spanning #Spain, #Portugal, #Italy, the #UK & Ireland, Sub-Saharan #Africa and now #SouthKorea.
👉https://buff.ly/OQsIayS
#vc #breastcancer #oncology #ysiosportfolio
👉https://buff.ly/OQsIayS
#vc #breastcancer #oncology #ysiosportfolio
May 21, 2026 at 12:15 PM
#PortfolioNews I Inbiomotion continues to expand its #international presence, with distribution partnerships spanning #Spain, #Portugal, #Italy, the #UK & Ireland, Sub-Saharan #Africa and now #SouthKorea.
👉https://buff.ly/OQsIayS
#vc #breastcancer #oncology #ysiosportfolio
👉https://buff.ly/OQsIayS
#vc #breastcancer #oncology #ysiosportfolio
🧪Don't miss this webinar by Dr. @rgergom.bsky.social (#IRBBarcelona-#Inbiomotion) that explores the biology & mechanism of action of the MAF gene, shedding light on its significant impact on patient outcomes.
@sourcebioscience.bsky.social
https://youtu.be/M7bvPjPQCq0?feature=shared
#BreastCancer
@sourcebioscience.bsky.social
https://youtu.be/M7bvPjPQCq0?feature=shared
#BreastCancer
Enjoy the videos and music that you love, upload original content and share it all with friends, family and the world on YouTube.
youtu.be
March 12, 2025 at 10:02 AM
🧪Don't miss this webinar by Dr. @rgergom.bsky.social (#IRBBarcelona-#Inbiomotion) that explores the biology & mechanism of action of the MAF gene, shedding light on its significant impact on patient outcomes.
@sourcebioscience.bsky.social
https://youtu.be/M7bvPjPQCq0?feature=shared
#BreastCancer
@sourcebioscience.bsky.social
https://youtu.be/M7bvPjPQCq0?feature=shared
#BreastCancer
🧪 The MAF Test®, developed by #IRBBarcelona & @icreacommunity.bsky.social spin-off Inbiomotion, is now available in South Korea.
This is the 1st #IRBBarcelona research-based product to reach patients there. The test could benefit ~34,000 new #BreastCancer patients each year.
👉 shorturl.at/qVsfh
This is the 1st #IRBBarcelona research-based product to reach patients there. The test could benefit ~34,000 new #BreastCancer patients each year.
👉 shorturl.at/qVsfh
May 21, 2026 at 10:49 AM
🧪 The MAF Test®, developed by #IRBBarcelona & @icreacommunity.bsky.social spin-off Inbiomotion, is now available in South Korea.
This is the 1st #IRBBarcelona research-based product to reach patients there. The test could benefit ~34,000 new #BreastCancer patients each year.
👉 shorturl.at/qVsfh
This is the 1st #IRBBarcelona research-based product to reach patients there. The test could benefit ~34,000 new #BreastCancer patients each year.
👉 shorturl.at/qVsfh
🧪 Big step for #PrecisionOncology: the g/IRBBarcelona%E2%80%93@icreacommunity.bsky.social%C2%A0spin-off" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#IRBBarcelona–@icreacommunity.bsky.social spin-off #Inbiomotion sees its MAF Test® included in the SEOM–GEICAM–SOLTI guidelines as a clinically relevant tool for more personalised treatment decisions in early-stage #BreastCancer.
🔗 https://shorturl.at/a1IOW
🔗 https://shorturl.at/a1IOW
January 30, 2026 at 10:02 AM
🧪 Big step for #PrecisionOncology: the g/IRBBarcelona%E2%80%93@icreacommunity.bsky.social%C2%A0spin-off" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#IRBBarcelona–@icreacommunity.bsky.social spin-off #Inbiomotion sees its MAF Test® included in the SEOM–GEICAM–SOLTI guidelines as a clinically relevant tool for more personalised treatment decisions in early-stage #BreastCancer.
🔗 https://shorturl.at/a1IOW
🔗 https://shorturl.at/a1IOW
Inbiomotion, the @irbbarcelona.org spin-off founded by #ICREAResearcher Roger Gomis, will bring the MAF Test® to patients in South Korea! 🏥
This test for identifying high-risk early-stage breast cancer patients is increasing its international projection. Congratulations!👏
This test for identifying high-risk early-stage breast cancer patients is increasing its international projection. Congratulations!👏
🧪 The MAF Test®, developed by #IRBBarcelona & @icreacommunity.bsky.social spin-off Inbiomotion, is now available in South Korea.
This is the 1st #IRBBarcelona research-based product to reach patients there. The test could benefit ~34,000 new #BreastCancer patients each year.
👉 shorturl.at/qVsfh
This is the 1st #IRBBarcelona research-based product to reach patients there. The test could benefit ~34,000 new #BreastCancer patients each year.
👉 shorturl.at/qVsfh
June 9, 2026 at 8:48 AM
Inbiomotion, the @irbbarcelona.org spin-off founded by #ICREAResearcher Roger Gomis, will bring the MAF Test® to patients in South Korea! 🏥
This test for identifying high-risk early-stage breast cancer patients is increasing its international projection. Congratulations!👏
This test for identifying high-risk early-stage breast cancer patients is increasing its international projection. Congratulations!👏
La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales
La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales
www.elperiodico.com
July 18, 2025 at 5:11 AM
La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales
La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales
La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales
www.elperiodico.com
July 17, 2025 at 4:26 AM
La catalana Inbiomotion lleva su test para predecir la gravedad de un cáncer de mama a los primeros hospitales
💡 Inbiomotion: test per predir metàstasis òssia en càncer de mama.
💡 LoopDX: diagnòstic ràpid de sèpsia a UCI.
💡 MAP-AD Test: predicció precoç de l’Alzheimer amb IA.
💡 Mediktor: assistent d’IA per orientar pacients al nivell assistencial adequat.
💡 LoopDX: diagnòstic ràpid de sèpsia a UCI.
💡 MAP-AD Test: predicció precoç de l’Alzheimer amb IA.
💡 Mediktor: assistent d’IA per orientar pacients al nivell assistencial adequat.
December 23, 2025 at 4:31 PM
💡 Inbiomotion: test per predir metàstasis òssia en càncer de mama.
💡 LoopDX: diagnòstic ràpid de sèpsia a UCI.
💡 MAP-AD Test: predicció precoç de l’Alzheimer amb IA.
💡 Mediktor: assistent d’IA per orientar pacients al nivell assistencial adequat.
💡 LoopDX: diagnòstic ràpid de sèpsia a UCI.
💡 MAP-AD Test: predicció precoç de l’Alzheimer amb IA.
💡 Mediktor: assistent d’IA per orientar pacients al nivell assistencial adequat.
#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion !
👉 Full details here - buff.ly/aT4nwud
#BreastCancer #Oncology #PortfolioNews #MAFTest
👉 Full details here - buff.ly/aT4nwud
#BreastCancer #Oncology #PortfolioNews #MAFTest
July 18, 2025 at 11:27 AM
#PortfolioNews I MAF Test® now adopted in top #Spanish hospitals to personalize early-stage #breast #cancer treatment. A major step for our #portfolio company #Inbiomotion !
👉 Full details here - buff.ly/aT4nwud
#BreastCancer #Oncology #PortfolioNews #MAFTest
👉 Full details here - buff.ly/aT4nwud
#BreastCancer #Oncology #PortfolioNews #MAFTest
🔬 Un nou test de pronòstic per al càncer de mama arriba als hospitals catalans
Un conjunt de centres públics i privats de Barcelona i Madrid, han estat els primers a incorporar el MAF Test®, desenvolupat per la biotech catalana Inbiomotion.
Un conjunt de centres públics i privats de Barcelona i Madrid, han estat els primers a incorporar el MAF Test®, desenvolupat per la biotech catalana Inbiomotion.
July 18, 2025 at 8:33 AM
🔬 Un nou test de pronòstic per al càncer de mama arriba als hospitals catalans
Un conjunt de centres públics i privats de Barcelona i Madrid, han estat els primers a incorporar el MAF Test®, desenvolupat per la biotech catalana Inbiomotion.
Un conjunt de centres públics i privats de Barcelona i Madrid, han estat els primers a incorporar el MAF Test®, desenvolupat per la biotech catalana Inbiomotion.
🧪 Top Spanish hospitals adopt the MAF Test® to transform #BreastCancer care.
#IRBBarcelona + ICREA spin-off #Inbiomotion launches the test in selected hospitals in Barcelona & Madrid—marking a step forward in personalized treatment.
Video credits: Telenotícies 3Cat
#CancerResearch #Innovation
#IRBBarcelona + ICREA spin-off #Inbiomotion launches the test in selected hospitals in Barcelona & Madrid—marking a step forward in personalized treatment.
Video credits: Telenotícies 3Cat
#CancerResearch #Innovation
August 22, 2025 at 9:03 AM
🧪 Top Spanish hospitals adopt the MAF Test® to transform #BreastCancer care.
#IRBBarcelona + ICREA spin-off #Inbiomotion launches the test in selected hospitals in Barcelona & Madrid—marking a step forward in personalized treatment.
Video credits: Telenotícies 3Cat
#CancerResearch #Innovation
#IRBBarcelona + ICREA spin-off #Inbiomotion launches the test in selected hospitals in Barcelona & Madrid—marking a step forward in personalized treatment.
Video credits: Telenotícies 3Cat
#CancerResearch #Innovation